***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Interleukin‐6  ( IL‐6 )  and  C‐reactive protein  ( CRP ) are elevated in prostate cancer patients , but the role of prediagnostic levels of these inflammatory mediators on prostate cancer outcomes is unclear . We undertook a large , prospect i ve case‐control study to evaluate the relation between prediagnostic levels of IL‐6 and CRP and prostate cancer incidence and mortality . We also investigated the role of the IL‐6 ( −174 G/C ) polymorphism in relation to circulating levels of  IL‐6 and CRP  , as well as cancer risk and mortality . We used unconditional logistic regression that adjusted for matching factors to analyze prostate cancer risk . For analyses of prostate cancer mortality , we conducted survival analyses in cases . Because of the strong link between inflammatory markers and body mass index ( BMI ) , we assessed interactions between BMI and plasma levels on prostate cancer outcomes . Neither IL‐6 nor CRP plasma levels varied significantly by IL‐6 genotype . Genotype was not associated with prostate cancer risk or survival . Though neither IL‐6 nor CRP was associated with prostate cancer incidence overall , we observed a statistically significant interaction between IL‐6 and BMI on prostate cancer incidence ( pinteraction < 0.01 ) . Increasing IL‐6 levels were positively associated with risk in healthy weight men , but inversely associated with risk in overweight men . Further , prediagnostic IL‐6 was associated with time to prostate cancer progression/death among healthy weight prostate cancer cases ( ptrend = 0.02 ) . Adjusted hazard ratios were 1.73 ( 95 % CI : 0.86 , 3.51 ) comparing the highest to lowest IL‐6 level . Our study suggests that IL‐6 may potentially be involved in the development or progression of prostate cancer . © 2008 Wiley‐Liss , 
    Output:
    
This study demonstrates that CRP may have a critical prognostic value in patients with prostatic cancer